11/12/2019

11/05/2019

Mylan Laboratories Limited - Unit 8

Center for Drug Evaluation and Research

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

United States: The Other Shoe Drops: FDA Withdraws 30-Year-Old Homeopathic Drug Enforcement Policy And Puts Industry On Notice Of Further Regulatory Pressure

Mintz

To anyone who has been following government enforcement and private litigation trends related to the over-the-counter (OTC) homeopathic drug industry over the past several years

United States: The FDA And FTC Join Forces In Issuing Warning Letter To CBD Product Company

Reed Smith

On October 22, 2019, the U.S. Food and Drug Administration ("FDA") and the Federal Trade Commission ("FTC") issued a public statement regarding a joint warning letter sent to Rooted Apothecary, LL